Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
J Pharm Pharmacol ; 2024 Jun 18.
Article in English | MEDLINE | ID: mdl-38888241

ABSTRACT

OBJECTIVES: This review highlights the current knowledge of polysaccharide from Lilii Bulbus, including the extraction, purification, structure, structure modification , biological activities and application, which will hopefully provide reference for further research and development of polysaccharide from Lilii Bulbus. MATERIALS AND METHODS: Literature searches were conducted on the following databases: Pubmed, ACS website, Elsevier, Google Scholar, Web of Science and CNKI database. Keywords such as "Lilii Bulbus", "polysaccharide", "preparation", "biological activities" and "application" were used to search relevant journals and contents, and some irrelevant contents were excluded. RESULTS: In general, the study of Lilium Bulbus polysaccharide extraction and purification, structure characterization and biological activity has made substantial progress, these findings highlight the lilium brownii polysaccharide enormous potential in biomedical applications, of lilium brownii polysaccharide laid a solid foundation for further research. DISCUSSION AND CONCLUSIONS: However, it should be noted that the relevant mechanism of the effective effect of lily bulb polysaccharide still needs to be worked on by researchers. These findings highlight the great potential of lily polysaccharides in biomedical applications, and lay a solid foundation for further research on lily polysaccharides.

2.
Microb Pathog ; 192: 106719, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38810768

ABSTRACT

Cimicifugae rhizoma is a traditional Chinese herbal medicine in China, and modern pharmacological research showed that it has obvious antiviral activity. Many polysaccharides have been proved to have immune enhancement and antiviral activity, but there are few studies on the biological activity of Cimicifuga rhizoma polysaccharide (CRP). The aim was to explore the character of CRP and its effects on improving immune activity and inhibiting transmissible gastroenteritis virus (TGEV). The monosaccharide composition, molecular weight, fourier transform infrared spectra and electron microscopy analysis of CRP was measured. The effect of CRP on immune activity in lymphocytes and RAW264.7 cells were studied by colorimetry, FITC-OVA fluorescent staining and ELISA. The effect of CRP on TGEV-infected PK-15 cells was determined using Real-time PCR, Hoechst fluorescence staining, trypan blue staining, acridine orange staining, Annexin V-FITC/PI fluorescent staining, DCFH-DA loading probe, and JC-1 staining. Network pharmacology was used to predict the targets of CRP in enhancing immunity and anti-TGEV, and molecular docking was used to further analyze the binding mode between CPR and core targets. The results showed that CRP was mainly composed of glucose and galactose, and its molecular weight was 64.28 kDa. The content of iNOS and NO in CRP group were significantly higher than the control group. CRP (125 and 62.5 µg/mL) could significantly enhance the phagocytic capacity of RAW264.7 cells, and imprive the content of IL-1ß content compared with control group. 250 µg/mL of CRP possessed the significant inhibitory effect on TGEV, which could significantly reduce the apoptosis compared to TGVE group and inhibit the decrease in mitochondrial membrane potential compared to TGVE group. The mRNA expression of TGEV N gene in CRP groups was significantly lower than TGEV group. PPI showed that the core targets of immune-enhancing were AKT1, MMP9, HSP90AA1, etc., and the core targets of TGE were CASP3, MMP9, EGFR, etc. Molecular docking show that CRP has binding potential with target. These results indicated that CRP possessed the better immune enhancement effect and anti-TGEV activity.


Subject(s)
Antiviral Agents , Molecular Docking Simulation , Polysaccharides , Transmissible gastroenteritis virus , Animals , Mice , Polysaccharides/pharmacology , Polysaccharides/chemistry , RAW 264.7 Cells , Transmissible gastroenteritis virus/drug effects , Antiviral Agents/pharmacology , Rhizome/chemistry , Interleukin-1beta/metabolism , Molecular Weight , Nitric Oxide Synthase Type II/metabolism , Nitric Oxide Synthase Type II/genetics , Cell Line , Lymphocytes/drug effects , Lymphocytes/immunology , Apoptosis/drug effects , Drugs, Chinese Herbal/pharmacology , Drugs, Chinese Herbal/chemistry , Spectroscopy, Fourier Transform Infrared , Monosaccharides , Nitric Oxide/metabolism , Immunologic Factors/pharmacology
3.
Int J Mol Sci ; 23(17)2022 Sep 01.
Article in English | MEDLINE | ID: mdl-36077364

ABSTRACT

The main toxic component of endotoxins released from the death or dissolution of Gram-negative bacteria is lipopolysaccharide (LPS), which exists widely in the natural environment, and a large amount of endotoxin can significantly inhibit the reproductive performance of animals. A previous study showed that endotoxins mainly damaged the physiological function of mucins in the endometrium, but the mechanism is not clear. In this study, the PI3K/Akt signaling pathway was not activated, and the NF-κB signaling pathway was inhibited by LPS treatment; the expression of occludin and E-cadherin proteins were decreased and ZO-1 protein expression was increased, because LPS can lead to the mucous layer becoming thinner, so that the embryonic survival rate is significantly reduced in early pregnancy. In middle and late pregnancy, LPS translocated to the epithelial cells of the uterus and the expression of claudin-1, JAMA, and E-cadherin proteins were decreased; at this time, a large number of glycosaminoglycan particles were secreted by endometrial gland cells through the PI3K/Akt/NF-κB signaling pathway that was activated after LPS treatment, However, there was no significant difference between the survival rates of fetal mice in the LPS (+) and LPS (-) groups. Glycosaminoglycan particles and mucins are secreted by gland cells, which can protect and maintain the pregnancy in the middle and late gestational periods.


Subject(s)
Lipopolysaccharides , Phosphatidylinositol 3-Kinases , Animals , Cadherins , Endometrium/metabolism , Endotoxins , Female , Glycosaminoglycans , Lipopolysaccharides/toxicity , Mice , Mucins , NF-kappa B/metabolism , Phosphatidylinositol 3-Kinases/metabolism , Pregnancy , Proto-Oncogene Proteins c-akt/metabolism
4.
Biochem Biophys Res Commun ; 629: 165-170, 2022 11 12.
Article in English | MEDLINE | ID: mdl-36122454

ABSTRACT

Hypoxic pulmonary hypertension (HPH) is a respiratory disease characterized by increased pulmonary vascular resistance and pulmonary arterial pressure. Persistent hypoxia alters the metabolic and transport functions of endothelial cells and promotes thrombosis and inflammation. Type 3 inositol-1,4,5-trisphosphate receptor (IP3R3) controls the release of calcium ions from the endoplasmic reticulum to the cytoplasm and mitochondria and is involved in cell proliferation, migration, and protein synthesis. In this study, we investigated the role and function of IP3R3 in HPH. The results showed that the expression level of IP3R3 was increased in pulmonary artery endothelial cells (PAECs) in a rat HPH model. The pulmonary artery pressure indices of IP3R3(-/-) mice with persistent hypoxia were significantly lower than those of HPH mice. The expression level of IP3R3 was significantly increased in hypoxia-treated PAECs. Knockdown of IP3R3 significantly inhibited the proliferation, migration and mesenchymal transition of PAECs induced by hypoxia. In conclusion, knockdown of IP3R3 can inhibit hypoxia-induced dysfunctions in PAECs, thus enabling IP3R3(-/-) mice to avoid HPH development. IP3R3 plays a key role in HPH and can be used as a potential target for the prevention and treatment of HPH.


Subject(s)
Hypertension, Pulmonary , Animals , Calcium/metabolism , Cell Proliferation , Endothelial Cells/metabolism , Hypertension, Pulmonary/metabolism , Hypoxia/complications , Hypoxia/genetics , Hypoxia/metabolism , Inositol/metabolism , Mice , Polyphosphates , Pulmonary Artery/metabolism , Rats
5.
Stem Cell Res Ther ; 13(1): 379, 2022 07 28.
Article in English | MEDLINE | ID: mdl-35902973

ABSTRACT

BACKGROUND: Acute kidney injury (AKI) is a complex disease and can be generally divided into prerenal, intrarenal, and postrenal AKI (PR-AKI). Previous studies have shown that mesenchymal stem cells (MSCs)-derived extracellular vesicles have protective function on prerenal and intrarenal AKI treatment, but whether they have therapeutic efficacy on PR-AKI remains unclear. In this study, we investigated the therapeutic efficacy of allogeneic adipose mesenchymal stem cell-derived extracellular vesicles (ADMSCEVs) on cat models of PR-AKI. METHODS: The cat models of PR-AKI were established by using artificial urinary occlusion and then treated with ADMSCEVs. Histopathological section analysis, blood routine analysis, plasma biochemical test, imaging analysis, and plasma ultra-high performance liquid chromatography-MS/MS (UHPLC-MS/MS) were performed to evaluate the therapeutic efficacy of ADMSCEVs. RESULTS: Physiological and biochemical test showed that the ADMSCEVs could recover creatinine, urea nitrogen and plasma phosphorus to homeostasis efficiently. Blood routine analysis showed that leukocytes in PR-AKI cats with ADMSCEVs treatment returned to normal physiological range more quickly than that of control. UHPLC-MS/MS analysis revealed that the plasma metabolome profile of PR-AKI cats treated with ADMSCEVs was highly similar to that of normal cats. Furthermore, UHPLC-MS/MS analysis also revealed six metabolites (carnitine, melibiose, D-Glucosamine, cytidine, dihydroorotic acid, stachyose) in plasma were highly correlated with the dynamic process of PR-AKI on cats. CONCLUSIONS: We demonstrate the efficacy of ADMSCEVs in the treatment of PR-AKI on cats. Our study also suggests six metabolites to be novel PR-AKI markers and to be potential targets for ADMSCEVs therapy. Our findings will be useful to improve clinical treatment of both animal and human PR-AKI patients with ADMSCEVs in the future.


Subject(s)
Acute Kidney Injury , Extracellular Vesicles , Hematopoietic Stem Cell Transplantation , Mesenchymal Stem Cell Transplantation , Mesenchymal Stem Cells , Acute Kidney Injury/pathology , Acute Kidney Injury/therapy , Animals , Extracellular Vesicles/pathology , Humans , Kidney/pathology , Male , Mesenchymal Stem Cell Transplantation/methods , Mesenchymal Stem Cells/pathology , Tandem Mass Spectrometry
6.
Front Vet Sci ; 8: 824170, 2021.
Article in English | MEDLINE | ID: mdl-35224078

ABSTRACT

The intestine is the most extensive storage organ of bacteria and endotoxins, and the mucosal immune system is the first barrier of the intestine. Mucin-2 (MUC2) is the major component of the mucus layers. In this study, we explored whether MUC2 plays a role in how lipopolysaccharide (LPS) invades the fetus from the gut to the uterus in pregnant mice. The results showed that the LPS levels of the ileum, colon, and uterus were significantly increased, and the content of secretory IgA (sIgA) in the ileum, colon, and uterus tissues was significantly decreased in the LPS(+) group on the 35th day after LPS treatment. On the 16th day of pregnancy, compared with the LPS(-) group, the level of ileum LPS was significantly decreased, and the content of LPS in the fetus was significantly increased in the LPS(+) group. The sIgA content in the fetus was significantly decreased in the uterus and placenta. The expression of MUC2 in the uterus, ileum, and colon was increased significantly in the LPS(+) group, especially in the uterus. It is suggested that endotoxins accumulate in the uterus during non-pregnancy. The high expression of MUC2 in the uterus can prevent LPS from translocating into uterine tissue. After pregnancy, MUC2 still protects uterine tissue, allowing a large amount of LPS to enter the fetal body through blood circulation. Therefore, the level of sIgA significantly decreased, resulting in a decline in fetal innate immune function.

7.
Int J Biol Macromol ; 117: 1211-1215, 2018 Oct 01.
Article in English | MEDLINE | ID: mdl-29894787

ABSTRACT

Zoletil is an anesthetic and immobilizing drug that has been used in the veterinary field for over 50 years; however, the effect of Zoletil, or its constituents, on brain cystathionine ß-synthase (CBS) remains unknown. Here, we aimed to determine the effect of Zoletil on rat brain CBS by administering a single intraperitoneal injection of the drug and examining hydrogen sulfide (H2S) and CBS levels in the cerebral cortex, hippocampus, and thalamus following three distinct behavioral phenotypes associated with the sedation procedure (e.g., loss of the righting reflex, return of the righting reflex, and return of walking). Zoletil administration resulted in significant decreases of endogenous H2S in the cerebral cortex, hippocampus, and thalamus, and H2S was observed to increase in these brain regions when rats recovered from the anesthesia. Quantitative real-time polymerase chain reaction, western blot, and immunohistochemistry revealed that CBS expression in the cerebral cortex and hippocampus exhibited the same trend as endogenous H2S following Zoletil administration. In summary, our results demonstrated that Zoletil induced the expression of CBS which could exert region-specific regulation of H2S in the cerebral cortex and hippocampus.


Subject(s)
Anesthetics/pharmacology , Brain/drug effects , Brain/metabolism , Cystathionine beta-Synthase/genetics , Gene Expression Regulation/drug effects , Tiletamine/pharmacology , Zolazepam/pharmacology , Anesthetics/administration & dosage , Animals , Cystathionine beta-Synthase/metabolism , Drug Combinations , Female , Hydrogen Sulfide/metabolism , Immunohistochemistry , Injections, Intraperitoneal , Male , Organ Specificity , Rats , Tiletamine/administration & dosage , Zolazepam/administration & dosage
8.
Theriogenology ; 103: 123-129, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28780483

ABSTRACT

BACKGROUND: The ingestion of locoweed that contains the toxic indolizidine alkaloid swainsonine (SW) disrupts ovarian function, accompanied by delayed estrus, increased estrous cycle length, delayed conception, and abortion. GOALS: The direct effects of SW on ovary cell steroidogenesis remain unclear. MATERIALS AND METHODS: In this study, Chinese hamster ovary (CHO) cells were used to investigate the effects of SW on estradiol (E2) secretion and cell viability and the mechanisms involved in these processes. RESULTS: CHO cells were treated with SW. 17 ß-Estradiol mRNA expression was decreased in the SW group compared to that in the control group. Various concentrations of E2 and SW were added to cultured cells for 12 h and 36 h. Compared to the control group cells, CYP19A1 expression was decreased in the SW and SW + E2 treatment groups at 12 h and 36 h (P < 0.05). This showed that SW mainly inhibits the last step of estrogen synthesis. When CHO cells were treated with SW, the p-Akt protein levels were significantly decreased compared to that in the control group cells at 12 h and 36 h (P < 0.05). However, the p-Akt expression in the SW + E2 group was not significantly different compared to that in the control group cells (P > 0.05). When CHO cells were treated with SW and SW + E2, the PI3K protein levels were significantly down-regulated compared to that in the control group cells at 12 h and 36 h. CONCLUSION: Taken together, these studies demonstrate that SW is an inhibitor of PI3K/Akt signaling pathway. However, SW blocked PI3K activation in estrogen induction without blocking p-Akt activation in CHO cells. Therefore, SW + E2 blocked upstream but did not affect the downstream of the PI3K/Akt signaling pathway.


Subject(s)
Estradiol/metabolism , Gene Expression Regulation, Enzymologic/drug effects , Ovary/drug effects , Phosphatidylinositol 3-Kinases/metabolism , Proto-Oncogene Proteins c-akt/metabolism , Swainsonine/pharmacology , Animals , CHO Cells , Cricetinae , Cricetulus , Enzyme Inhibitors/pharmacology , Female , Ovary/metabolism
9.
Biomed Res Int ; 2016: 6824374, 2016.
Article in English | MEDLINE | ID: mdl-27999809

ABSTRACT

Swainsonine is the primary toxin in locoweeds. It causes intention tremors, reproductive dysfunction, emaciation, and death. The objective of the present study was to evaluate the potential reproductive and developmental toxicities caused by swainsonine in mice. The treatment groups consisting of three generations of mice were given a range of concentrations of swainsonine by intraperitoneal injection (2.50 mg/kg body weight (BW), 1.20 mg/kg BW, 0.60 mg/kg BW, and 0 mg/kg BW). The 0 mg/kg BW group exhibited significantly fewer estrous cycles and an increased number of estrous ones compared to the 2.50 mg/kg BW, 1.20 mg/kg BW, and 0.60 mg/kg BW groups (P < 0.05). All three generations of mice treated with swainsonine had significantly higher spleen, liver, and kidney indices and significantly lower body weights compared to the 0 mg/kg BW group (P < 0.05). For the first and second generations of treatment group, the copulation indices and the numbers of live pups on postnatal days (PND) 0, 4, and 15 were significantly decreased compared to those of the 0 mg/kg BW group (P < 0.05). The fertility and gestation indices of the treatment group of the first generation were significantly increased compared to the 2.50 mg/kg BW, 1.20 mg/kg BW, and 0.60 mg/kg BW groups of the second generation (P < 0.05). Cumulatively, these results indicate that swainsonine may cause reproductive and developmental toxicities in mice in both parents and offspring.


Subject(s)
Fertility/drug effects , Oxytropis/chemistry , Prenatal Exposure Delayed Effects , Swainsonine/toxicity , Animals , Female , Male , Mice , Pregnancy , Prenatal Exposure Delayed Effects/chemically induced , Prenatal Exposure Delayed Effects/metabolism , Prenatal Exposure Delayed Effects/pathology , Prenatal Exposure Delayed Effects/physiopathology , Swainsonine/chemistry
10.
Vet Anaesth Analg ; 38(4): 301-9, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21672125

ABSTRACT

OBJECTIVE: To evaluate the antagonistic effects of atipamezole (ATI), flumazenil (FLU) and naloxone (NAL) alone and in various combinations following administration of tiletamine-zolazepam-xylazine-tramadol. STUDY DESIGN: Prospective, experimental, randomized cross-over study. ANIMALS: Eight Chinese miniature pigs (three females and five males) mean age 8 (range 7-10) months and bodyweight 57.5 (52.4-62.1) kg. METHODS: All animals were anaesthetized with tiletamine/zolazepam (3.0 mg kg(-1)), xylazine (1.2 mg kg(-1)) and tramadol (1.6 mg kg(-1)) given intramuscularly (IM). Thirty minutes later, one of eight treatments was administered IM: saline control, ATI (0.12 mg kg(-1)), FLU (0.1 mg kg(-1)), NAL (0.03 mg kg(-1)), ATI-FLU, FLU-NAL, ATI-NAL or ATI-FLU-NAL. After injection of antagonists the following times were recorded: to recovery of the palpebral, pedal and tail clamp reflexes, to head movement, sternal recumbency, standing and walking. Posture, sedation, analgesia, jaw relaxation and auditory response were scored at set times until 120 minutes after injection of antagonists. Heart rates, respiratory rates and rectal temperature were measured at those times. Data were analyzed by anova for repeated measures, followed by the Tukey's test to compare differences between means, or by Kruskal-Wallis test as appropriate. RESULTS: FLU, NAL alone, or FLU-NAL did not effectively antagonize anaesthesia induced by tiletamine/zolazepam-xylazine-tramadol. ATI, ATI-FLU, ATI-NAL and ATI-FLU-NAL produced an immediate and effective recovery from anaesthesia. The combination of ATI-FLU-NAL was the most effective combination in antagonizing the anaesthetic effect. Adverse effects such as tachycardia, tachypnoea, excitement and muscle tremors were not observed during this study. CONCLUSION AND CLINICAL RELEVANCE: ATI-FLU-NAL is the most effective combination for antagonizing tiletamine/zolazepam-xylazine-tramadol anaesthesia in pigs. However, ATI alone or in various combinations also provides effective antagonism.


Subject(s)
Adrenergic alpha-2 Receptor Antagonists/pharmacology , Anesthetics/antagonists & inhibitors , Flumazenil/pharmacology , GABA Modulators/pharmacology , Imidazoles/pharmacology , Naloxone/pharmacology , Narcotic Antagonists/pharmacology , Adrenergic alpha-2 Receptor Antagonists/administration & dosage , Anesthesia Recovery Period , Anesthetics/administration & dosage , Animals , Cross-Over Studies , Drug Antagonism , Drug Combinations , Female , Flumazenil/administration & dosage , GABA Modulators/administration & dosage , Imidazoles/administration & dosage , Male , Naloxone/administration & dosage , Narcotic Antagonists/administration & dosage , Prospective Studies , Swine , Tiletamine/administration & dosage , Tiletamine/antagonists & inhibitors , Tramadol/administration & dosage , Tramadol/antagonists & inhibitors , Xylazine/administration & dosage , Xylazine/antagonists & inhibitors , Zolazepam/administration & dosage , Zolazepam/antagonists & inhibitors
SELECTION OF CITATIONS
SEARCH DETAIL
...